Shopping Cart

Your shopping cart is currently empty

Minalrestat

Name: Minalrestat
Brand: TargetMol
SKU: T33389
Price: 258 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T33389Cas No. 129688-50-2

Alias WAYARI-509, WAY-ARI-509, WAY-121509, WAY121509, ARI-509, ARI509

Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.

Minalrestat

Copy Product Info

🥰Excellent

Purity: 99.88%

Catalog No. T33389Alias WAYARI-509, WAY-ARI-509, WAY-121509, WAY121509, ARI-509, ARI509Cas No. 129688-50-2

Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$258	In Stock	In Stock
5 mg	$642	In Stock	In Stock
10 mg	$913	In Stock	In Stock
25 mg	$1,370	In Stock	In Stock
50 mg	$1,850	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.88%

Appearance:Solid

Color:White

Resource Download

COA HPLC FNMR HNMR

Product Introduction

Bioactivity

Description	Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.
In vitro	Minalrestat (100 μM) reduces intracellular sorbitol content in primary cultured rat cells without affecting intracellular glucose levels.[3] Minalrestat (100 μM, 48 h) causes the accumulation of PKC-α and -β2 in primary cultured rat mesangial cells.[3]
In vivo	The diabetic group was treated from 3 days after the alloxan injection with Minalrestat (10 mg/kg/day) for 30 days and the Minalrestat treatment (10 mg/kg/day/7 days) of galactosemic rats started concomitantly with the induction of galactosemia. The impaired responses to bradykinin, histamine, and platelet-activating factors of arterioles and venules observed in diabetic and galactosemic rats were completely prevented by Minalrestat. Neither diabetes nor galactosemia affected responses to acetylcholine and sodium nitroprusside. Responses to these agents were not modified by aldose reductase inhibition. The restoring effect of Minalrestat was reversed by inhibition of nitric oxide (NO) synthesis with N(omega)-nitro-L-arginine methyl ester, by blocking K(+) channel with tetraethylammonium but not by cyclooxygenase inhibition with diclofenac.[1]
Synonyms	WAYARI-509, WAY-ARI-509, WAY-121509, WAY121509, ARI-509, ARI509

Chemical Properties

Molecular Weight	449.2
Formula	C₁₉H₁₁BrF₂N₂O₄
Cas No.	129688-50-2
Smiles	O=C1C2(C=3C(C(=O)N1CC4=C(F)C=C(Br)C=C4)=CC=C(F)C3)CC(=O)NC2=O
Relative Density.	1.79g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 45 mg/mL (100.18 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2262 mL	11.1309 mL	22.2618 mL	111.3090 mL
5 mM	0.4452 mL	2.2262 mL	4.4524 mL	22.2618 mL
10 mM	0.2226 mL	1.1131 mL	2.2262 mL	11.1309 mL
20 mM	0.1113 mL	0.5565 mL	1.1131 mL	5.5654 mL
50 mM	0.0445 mL	0.2226 mL	0.4452 mL	2.2262 mL
100 mM	0.0223 mL	0.1113 mL	0.2226 mL	1.1131 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc